论文部分内容阅读
目的 探讨血清DNA 3号染色体短臂 (3p1 4 ,2 5)等位基因杂合性丢失与卵巢癌发生、发展的相关性。方法 采用聚合酶链反应并结合二核苷酸重复序列多态性方法 ,分别对 38例卵巢癌及8例卵巢良性肿瘤患者的血清DNA 3p1 4 ,2 5的 4个微卫星位点 (D3S1 0 2 9、D3S1 2 2 8、D3S1 30 0、D3S1 4 81 )杂合性丢失进行检测。另外 ,检测 38例中 1 8例患者的组织及相应血清DNA 3p1 4 ,2 5杂合性丢失。结果 1 8例卵巢癌血清与肿瘤组织DNA 3p1 4 ,2 5基因 4个微卫星位点杂合性丢失率之间存在明显的相关性 (P <0 0 5)。 38例血清DNA标本中有 2 9例 (76 % )至少在 1个微卫星位点出现杂合性丢失 ,1 7例(45 % )有 2个以上微卫星位点出现杂合性丢失。卵巢癌Ⅱ期、Ⅲ期、Ⅳ期出现杂合性丢失率分别为 2 /4、78%、8/ 9。卵巢癌病理类型仅在微卫星D3S1 0 2 9位点的杂合性丢失率比较 ,差异有显著性 (P=0 0 0 74)。8例良性肿瘤组织及血清均未出现杂合性丢失。结论 卵巢癌患者血清DNA与肿瘤组织DNA 3p1 4 ,2 5出现杂合性丢失密切相关 ,血清 3p1 4 ,2 5出现杂合性丢失率与卵巢癌恶性程度有关。
Objective To investigate the relationship between loss of heterozygosity of short arm (3p1 4, 25) alleles and the occurrence and development of ovarian cancer on chromosome 3 of serum DNA. Methods Polymerase chain reaction (PCR) combined with dinucleotide repeat polymorphism (PCR-RFLP) method was used to detect the polymorphisms of 3p14, 25 and 4 microsatellite loci in 38 patients with ovarian cancer and 8 patients with benign ovarian tumors (D3S10 2 9, D3S1 2 2 8, D3S1 30 0, D3S1 4 81) loss of heterozygosity. In addition, the detection of 38 cases in 38 cases of patients and the corresponding serum DNA 3p14, 25 loss of heterozygosity. Results There was a significant correlation between the loss rate of heterozygosity at 4 microsatellite loci in 18 cases of ovarian cancer serum and tumor DNA 3p14 and 25 genes (P <0.05). Of the 38 serum samples, 29 (76%) had loss of heterozygosity in at least one microsatellite locus, and 17 (45%) had more than 2 microsatellite loci. Ovarian cancer Ⅱ, Ⅲ, Ⅳ loss of heterozygosity were 2/4, 78%, 8/9. The heterozygous loss rate of ovarian cancer pathological type only in the microsatellite D3S1 0 29 sites was significantly different (P = 0 0 0 74). None of the 8 cases of benign tumor and serum loss of heterozygosity. Conclusion Serum DNA of patients with ovarian cancer is closely related to the loss of heterozygosity of DNA 3p14, 25 in the tumor tissue. The loss of heterozygosity in the serum 3p14, 25 is related to the malignant degree of ovarian cancer.